. However, the authors also assert that major arguments suggesting differences in AIRE in humans and mice have been invalidated. From a translational point of view this is a crucial point, and, as researchers studying both AIRE-deficient mice and humans, we beg to differ.
The clinical difference between patients with APECED 4 and the originally described Aire-knockout mouse 2, 5 , which was on a C57Bl/6 × 129/Cv genetic background, is acknowledged by Mathis and Benoist, but they suggest that because on other genetic backgrounds the mouse disease is very severe, this difference is irrelevant. They do not mention that in a paper they cite 6 Aire-deficient non-obese diabetic (NOD) mice are in fact the only animals to become sick.
In the NOD background the disease manifests as fulminant exocrine pancreatitis, a characteristic which has not been described in human APECED 4 . On the other hand, diabetes is often part of APECED, but, in Aire-deficient NOD mice, pancreatic islets are intact even though insulin expression in the mouse thymus is controlled by Aire 2 . As for the other mouse strains, Mathis and Benoist inaccurately equate immunopathological findings, such as autoantibodies and infiltrating lymphocytes, with autoimmune disease, without any evidence of excess mortality, morbidity or even tissue damage. Analogous situations are commonplace in medicine. It is well known that a certain fraction of apparently healthy individuals will test positive for autoantibodies 7, 8 . Yet there is no evidence of any autoimmune disease, and in the majority of these individuals the presence of autoantibodies does not predict future autoimmunity. Similar to the situation in Aire-knockout mice, these individuals have immunopathological findings but no disease. By contrast, without appropriate hormone replacement therapy the main endocrinological deficiencies in APECED are fatal.
A further claim in the article is that differences in autoantigens 9 and target organs are only to be expected, given the differences in the genes that encode MHC molecules in the two species. This disregards the fact that, in patients with APECED, the targets of autoimmunity are often quite conserved between individuals 10 , and the phenotype of the disease is only weakly correlated with HLA type or other non-AIRE genes [11] [12] [13] . Indeed, the strong influence of non-Aire genes on the mouse phenotype is another clear difference between the two species, not a reason to dismiss the discrepancies.
We believe that, far from invalidating, the current data tend to support the view that AIRE-deficiency leads to a different phenotype in humans and mice. This may be due to differences in AIRE function or, perhaps more probably, in the physiological environment in which AIRE function takes place. We have elsewhere 14 suggested that thymic architecture and the role of Hassall's corpuscles in supporting human regulatory T-cell development 15 might be involved in the dissimilar clinical outcome in the two species. Uncovering the reasons for the species-dependent differences should reveal important aspects of human autoimmunity.
